Erdheim-Chester病心脏受累的患病率、模式与结局
该研究回顾性纳入200例Erdheim-Chester病(ECD)患者,分析心脏磁共振(CMR)所示心脏受累的患病率、临床特征及预后。结果显示48%患者存在心脏受累,与BRAFV600E突变及ECD相关临床事件相关,但多因素分析未显示与更低生存率相关。
要点
- 近半数ECD患者存在心脏受累,右房室沟浸润最常见(37%)。
- 心脏受累与BRAFV600E突变(OR=7.4)及ECD相关临床事件(OR=5)独立相关。
- 心脏受累未显著增加全因死亡风险(校正HR=1.4,P=0.2)。
核心结论
- ECD患者中心脏受累患病率约48%,与BRAFV600E突变及心包炎、心包填塞、传导障碍等并发症相关,但多因素分析未显示与更低生存率独立相关。
研究设计与样本
- 回顾性纳入2003至2019年法国三级中心接受心脏磁共振(CMR)检查的200例ECD患者,中位年龄63岁(范围54-71),女性占30%,BRAFV600E突变者占58%,中位随访5.5年(范围3.3-9年)。
主要发现
- CMR显示右房室沟浸润占37%,心包积液占24%;心包炎8例(4%),其中心包填塞10例(5%),ECD相关高度传导障碍5例(2.5%),冠心病45例(23%)。
- 心脏受累96例(48%),与BRAFV600E突变独立相关(OR=7.4,95%CI 3.5-16.8,P<0.001),并与ECD相关临床事件相关(OR=5,95%CI 1.5-21.2,P=0.004)。
- 多因素分析中,心脏受累与全因死亡风险无显著独立关联(校正HR=1.4,95%CI 0.8-2.5,P=0.2)。
关键数值与推荐
- 心脏受累定义为CMR显示右房室沟浸润、心包积液、心包炎、心包填塞、传导障碍或冠心病等表现,本研究中48%患者符合。
临床怎么用
- 对ECD患者应关注心脏受累筛查,尤其BRAFV600E突变者,需警惕心包炎、心包填塞及传导障碍等并发症。
- 心脏受累未显著影响生存,临床管理应侧重并发症的识别与处理。
局限性
- 回顾性单中心设计,仅纳入接受CMR检查的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cardiac involvement of Erdheim-Chester disease (ECD), a rare L group histiocytosis, has been reported to be associated with poor outcomes, but systematic studies are lacking. The present study aimed to investigate the prevalence, clinical features, imaging features, and prognosis of cardiac involvement in ECD in a large series. METHODS AND RESULTS: All patients with ECD who underwent cardiac magnetic resonance (CMR) imaging between 2003 and 2019 at a French tertiary center were retrospectively included. Primary outcome was all-cause mortality. Secondary outcomes were pericarditis, cardiac tamponade, conduction disorders, device implantation and coronary artery disease (CAD). A total of 200 patients were included [63 (54-71) years, 30% female, 58% BRAFV600E mutated]. Median follow-up was 5.5 years (3.3-9 years). On CMR, right atrioventricular sulcus infiltration was observed in 37% of patients, and pericardial effusion was seen in 24% of patients. In total, 8 patients (4%) had pericarditis (7 acute, 1 constrictive), 10 patients (5%) had cardiac tamponade, 5 patients (2.5%) had ECD-related high-degree conduction disorders, and 45 patients (23%) had CAD. Overall, cardiac involvement was present in 96 patients (48%) and was associated with BRAFV600E mutation [Odds ratio (OR) = 7.4, 95% confidence interval (CI) (3.5-16.8), P < 0.001] and ECD-related clinical events [OR = 5, 95%CI (1.5-21.2), P = 0.004] but not with lower survival in multivariate analysis [adjusted hazard ratio (HR) = 1.4, 95% CI (0.8-2.5), P = 0.2]. CONCLUSION: Cardiac involvement is present in nearly half of ECD patients and is associated with BRAFV600E mutation and complications (pericarditis, cardiac tamponade, and conduction disorders) but not with lower survival.
引用
- Azoulay LD, Bravetti M, Cohen-Aubart F, et al. Prevalence, patterns and outcomes of cardiac involvement in Erdheim-Chester disease. Eur Heart J. 2023. PMID: 36545799. doi:10.1093/eurheartj/ehac741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。